Eli Lilly Acquires Ventyx Biosciences for $1.2 Billion
Eli Lilly has announced an all-cash acquisition of Ventyx Biosciences for $1.2 billion. This move marks a strategic expansion beyond its diabetes and weight-loss drug franchises, signaling a diversification of revenue streams.
Insights:
In a significant move to diversify its product offerings, Eli Lilly and Company has announced an all-cash acquisition of Ventyx Biosciences Inc for $1.2 billion. The announcement, made on January 7, 2026, underscores Eli Lilly's strategic pivot to broaden its therapeutic portfolio beyond its well-established diabetes and weight-loss drug franchises.
